GIANNANTONI, ANTONELLA
 Distribuzione geografica
Continente #
NA - Nord America 30.016
EU - Europa 17.410
AS - Asia 12.049
SA - Sud America 3.702
AF - Africa 632
OC - Oceania 68
Continente sconosciuto - Info sul continente non disponibili 48
Totale 63.925
Nazione #
US - Stati Uniti d'America 29.689
SG - Singapore 4.359
CN - Cina 3.942
GB - Regno Unito 3.254
BR - Brasile 3.131
IE - Irlanda 3.055
RU - Federazione Russa 2.779
FR - Francia 2.433
UA - Ucraina 2.271
IT - Italia 1.520
HK - Hong Kong 1.264
VN - Vietnam 1.255
SE - Svezia 1.112
NG - Nigeria 355
FI - Finlandia 315
DE - Germania 280
AR - Argentina 212
BD - Bangladesh 198
IN - India 190
CA - Canada 154
NL - Olanda 130
TR - Turchia 124
ID - Indonesia 113
IQ - Iraq 109
EC - Ecuador 105
ZA - Sudafrica 105
MX - Messico 78
AU - Australia 63
PK - Pakistan 61
KR - Corea 60
CO - Colombia 55
JP - Giappone 50
VE - Venezuela 49
MY - Malesia 48
SA - Arabia Saudita 48
CL - Cile 47
MA - Marocco 47
EU - Europa 46
PY - Paraguay 42
AT - Austria 41
UZ - Uzbekistan 36
PL - Polonia 28
PE - Perù 27
EG - Egitto 26
KE - Kenya 26
RO - Romania 26
AE - Emirati Arabi Uniti 25
UY - Uruguay 23
RS - Serbia 22
BE - Belgio 21
ES - Italia 21
JO - Giordania 21
KZ - Kazakistan 18
OM - Oman 18
TN - Tunisia 16
BG - Bulgaria 15
CH - Svizzera 15
DZ - Algeria 15
NP - Nepal 15
AZ - Azerbaigian 14
JM - Giamaica 14
IL - Israele 13
BZ - Belize 12
CR - Costa Rica 12
BO - Bolivia 11
CI - Costa d'Avorio 11
DO - Repubblica Dominicana 11
AL - Albania 10
TT - Trinidad e Tobago 10
AO - Angola 9
HN - Honduras 9
LB - Libano 9
GR - Grecia 8
IR - Iran 8
SV - El Salvador 8
BY - Bielorussia 7
IM - Isola di Man 7
AM - Armenia 6
SN - Senegal 6
GE - Georgia 5
HU - Ungheria 5
NZ - Nuova Zelanda 5
PH - Filippine 5
SY - Repubblica araba siriana 5
BB - Barbados 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
HR - Croazia 4
PA - Panama 4
TH - Thailandia 4
KG - Kirghizistan 3
KH - Cambogia 3
KW - Kuwait 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
MD - Moldavia 3
MK - Macedonia 3
NI - Nicaragua 3
PR - Porto Rico 3
QA - Qatar 3
Totale 63.877
Città #
Dallas 10.081
Dublin 2.973
Southend 2.970
Jacksonville 2.524
Fairfield 2.287
Singapore 1.762
Hong Kong 1.253
Chandler 1.191
Ashburn 1.106
Princeton 1.018
Woodbridge 1.016
Wilmington 988
Seattle 838
Beijing 813
Houston 798
Cambridge 779
The Dalles 691
Nanjing 683
San Mateo 512
Santa Clara 503
Moscow 485
Lauterbourg 449
Ho Chi Minh City 437
Abuja 353
Ann Arbor 308
Helsinki 294
Hanoi 266
San Jose 257
Boardman 235
Los Angeles 226
Nanchang 225
Buffalo 224
Redondo Beach 223
São Paulo 216
San Diego 203
New York 189
Siena 155
Dearborn 154
Shenyang 151
Changsha 136
Tianjin 133
Hebei 119
Milan 113
Rome 109
Hefei 98
Jiaxing 94
Rio de Janeiro 84
Shanghai 84
Toronto 81
San Francisco 79
Norwalk 76
Kunming 72
Belo Horizonte 69
London 64
Da Nang 62
Izmir 60
Seoul 58
Haiphong 56
Frankfurt am Main 54
Johannesburg 53
Curitiba 52
Guangzhou 51
Dhaka 49
Orem 48
Porto Alegre 48
Guarulhos 43
Tokyo 43
Brasília 42
Chicago 39
Amsterdam 38
Salvador 37
Zhengzhou 37
Bologna 35
Munich 35
Baghdad 34
Council Bluffs 34
Naples 34
Sydney 34
Kuala Lumpur 33
Vienna 33
Jinan 32
Quito 31
Ribeirão Preto 31
Campinas 30
Santo André 30
Goiânia 29
Guayaquil 29
Lanzhou 28
Sorocaba 28
Tashkent 28
Brooklyn 27
Biên Hòa 26
Columbus 26
Florence 26
Thái Bình 26
Manaus 25
Manchester 25
Nuremberg 25
Hải Dương 24
Palermo 24
Totale 42.939
Nome #
1 hour pad test ha un basso valore predittivo nella diagnosi dell’incontinenza urinaria femminile 7.617
DIAGNOSI ECOGRAFICA DI DEFICIT SFINTERICO URETRALE NELLA DONNA 482
Utilizzo degli Alfa-litici nelle donne con sintomi del basso tratto urinario 284
1-hour pad test has low predictive value in the diagnosis of women with urinary incontinence 258
A Camey II Modified Neobladder: Long-Term Complications And Functional Results 234
Urodynamic findings and functional outcomes after laparoscopic sacrocolpopexy for symptomatic pelvic organ prolapse 233
A Camey II Modified Neobladder: Long-Term Complications And Functional Results 211
Pharmacologic goals in interstitial cystitis/bladder pain syndrome 200
"Voiding dysfunction in post-comatose patients" 189
Adolescence transitional care in neurogenic detrusor overactivity and the use of OnabotulinumtoxinA: A clinical algorithm from an Italian consensus statement 189
"Advanced analysis in the pressure flow-study: a comparison of methods". 187
The Splicing Factor PTBP1 Promotes Expression of Oncogenic Splice Variants and Predicts Poor Prognosis in Patients with Non-muscle-Invasive Bladder Cancer 179
"PSYCHOLOGICAL INVESTIGATION AND SEXUAL DYSFUNCTION IN SPINAL CORD INJURY WOMEN 177
Food-Specific IgG4 Antibody-Guided Exclusion Diet Improves Conditions of Patients with Chronic Pain 176
Association between selenium and lycopene supplementation and incidence of prostate cancer: Results from the post-hoc analysis of the procomb trial 176
"Anal sphincterometry: is it a good alternative to perineal floor EMG recordings?." 175
"Psychological investigation and sexual dysfunction in spinal cord injury women". 173
Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson's disease: a pilot study 172
The impact of Mirabegron on sexual function in women with idiopathic overactive bladder 171
"Continuous ambulatory urodynamic monitoring: its role in diagnosing female micturitional disorders" 170
"In vitro study of passive vs electromotive mitomycin C diffusion in human bladder wall. Preliminary results". 170
"In reply to Dr Silver" 170
"Comparison of cystometric patterns in spinal cord injury and multiple sclerosis patients" 170
"Vesciche ileali di sostituzione: studio morfo-funzionale" 170
Sensitivity and specificity of one-hour pad test as a predictive value for female urinary incontinence 170
"Intravesical Capsaicin in the treatment of hyperactive bladder in Spinal Cord injury (SCI) patients". 169
"Clean intermittent catheterization prevents upper urinary tract disease in long-term spinal cord injured (SCJ) patients" 168
"Valutazione neuro-urologica ed endoscopica ed attuali orientamenti terapeutici" 167
Usefulness of antibiotic prophylaxis in invasive urodynamics in fertile and in postmenopausal female subjects 167
Single-session supine bilateral percutaneous nephrolithotomy 164
"Neurological features and urological dysfunction in survivors from prolonged coma". 162
Dyssynergia or asynergia? 162
Endoscopic ballistic lithotripsy in the treatment of Bladder Calculi in patients with Neurogenic Voiding Dysfunction 160
Cystoman® and calculi: a good alternative to standard therapies in preventing stone recurrence 159
Desmopressin in the treatment of nocturia in patients affected by Parkinson's disease 158
Intravesical resiniferatoxin versus capsaicin in the treatment of detrusor hypereflexia in spinal cord injured patients 157
An Updated Systematic Review and Statistical Comparison of Standardised Mean Outcomes for the Use of Botulinum Toxin in the Management of Lower Urinary Tract Disorders 156
Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System 155
"The Nocturnal alarm as a conditioning therapy in primary nocturnal enuresis" 154
Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study 154
Bacillus Calmette-Guérin versus Gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study 154
Bcg vs. Gemcitabina per la terapia endovescicale del carcinoma uroteliale ad alto rischio: Studio prospettico randomizzato 153
"Management of functional voiding dysfunction in children by means of voiding biofeedback" 153
Desmopressin in the treatment of nocturia in patients affected by neurogenic bladder 152
Thalidomide as therapy for the chronic pelvic pain syndrome (CPPS) 151
Lower urinary tract symptoms and urodynamic dysfunctions in clinically isolated syndromes suggestive of multiple sclerosis 151
Resonance® metallic stent in patients with ureterocutaneostomies 151
Nerve Growth Factor bladder tissue levels in patients with benign prostatic hyperplasia and detrusor overactivity treated with tamsulosin. 151
Urgency of micturition and detrusor contractility in men with prostatic obstruction and overactive bladders 150
Assessment of botulinum A toxin high affinity SV2 receptors on normal human urothelial cells. 149
Bladder and urethral sphincter function after radical retropubic prostatectomy: A prospective long-term study 148
Prostasomes and prostate cancer 148
Two-year efficacy and safety of botulinum A toxin intravesical injections in patients affected by refractory painful bladder syndrome 147
Long-term efficacy of the trans-obturator and retropubic mid-urethral slings for stress urinary incontinence: update from a randomized clinical trial 147
Serenoa repens + selenium + lycopene vs tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: a Phase IV, non-inferiority, open-label, clinical study (SPRITE study) 147
Lower urinary tract symptoms and urodynamic dysfunctions in clinically isolated syndromes suggestive of multiple sclerosis 146
Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder 146
Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup 145
“Efficacy and tolerability of fesoterodine fumarate in the treatment of overactive bladder symptoms in patients affected by Multiple Sclerosis: Long term follow up” 145
Sequential intravesical bacillus Calmette-Guerin and electromotive mitomycin-C for high risk superficial bladder cancer: a prospective controlled study 145
Dermatomyositis Associated with Testicular Germ Cell Cancer 145
Botulinum A toxin intravesical injections improves sexual function in female patients affected by neurogenic detrusor overactivity 144
PUMA vs Romanzi in the detection of female bladder obstruction and detrusor contractility. 144
Editorial comment on: Complete continence after botulinum neurotoxin type a injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks 144
Patient-reported outcomes in bladder pain syndrome: qui auget dolorem, auget et scientiam (as pain increases, so increases knowledge) 143
Clinical and neurophysiologic study of botulinum A toxin effect on neurogenic and idiopathic detrusor overactivity 143
New frontiers in intravesical therapies and drug delivery 142
A prospective randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease 142
Botulinum-A toxin injections into the detrusor muscle reduce nerve growth factor bladder tissue levels in patients affected by neurogenic detrusor overactivity. 142
The Efficacy and Safety of Duloxetine in a Multidrug Regimen for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 141
Triage of functional, female and neuro-urology patients during and immediately after the COVID-19 outbreak 141
Stability of Resiniferatoxin stock solutions 140
Does the neobladder filling modulate soleus H reflex? 140
Intravesical administration of botulinum A toxin in spinal cord injured patients. Suburothelial versus intradetrusorial injections 140
Must colposuspension be associated with sacropexy to prevent postoperative urinary incontinence? 140
Botulinum A toxin modulates afferent fibers in neurogenic detrusor overactivity 140
Six-year follow-up of intradetrusorial injections of botulinum toxin type A in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results 139
Intradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study 139
Treatment of neurogenic bladder in spinal cord injury (SCI) patients by means of clean intermittent catheterization (CIC): prevention of renal disease 139
Onabotulinumtoxin-A intradetrusorial injections modulate bladder expression of NGF, TrkA, p75 and TRPV1 in patients with detrusor overactivity 139
Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group 138
Botulinum toxin a enters normal human urothelial cells and modulates the sensory activity of bladder urothelium 138
Urological dysfunctions and upper urinary tract involvement in multiple sclerosis (MS) patients 138
Multicenter, randomized, phase III trial comparing radical retropubic prostatectomy with conventional external beam radiotherapy for localized prostate cancer: An interim report 138
Preoperative MUCP and VLPP Did Not Predict Long-Term (4-Year) Outcome after Transobturator Mid-Urethral Sling 137
Urinary symptoms and sexual dysfunction in patients affected by multiple sclerosis 137
Intermittent catheterization with a prelubricated catheter in spinal cord injured patients: a prospective randomized crossover study 137
Voiding dysfunction after radical retropubic prostatectomy: More than external urethral sphincter deficiency 136
Linking age, cystocele and abdominal straining 136
Normal human urothelial cell lines express onabotulinumtoxinA SV2 high affinity receptors 136
Comparative bladder wall tissue levels of resiniferatoxin 136
Psychological investigation in spinal cord injury patients. 136
Intravesical resiniferatoxin versus botulinum A toxin injections for the treatment of neurogenic detrusor overactivity 135
Voiding Dysfunction in Patients With Spinal Cord Lesions at the Thoraco-Lumbar Vertebral Junction 135
Is the one-hour pad-test useful in the assessment of urinary stress incontinence? 135
Thalidomide as therapy for the chronic pelvic pain syndrome (CPPS) 135
Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis 135
Urinary symptoms and sexual dysfunction in patients affected by multiple sclerosis 134
Linking age, cystocele and abdominal straining 134
Intravesical resiniferatoxin versus botulinum-A toxin injections for the treatment of neurogenic detrusor overactivity. 134
Totale 23.441
Categoria #
all - tutte 205.674
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 205.674


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021342 0 0 0 0 0 0 0 0 0 0 0 342
2021/20224.737 257 459 556 377 31 133 66 254 187 591 342 1.484
2022/20236.043 542 162 961 1.178 549 1.433 60 360 532 67 115 84
2023/20243.317 152 87 273 92 83 990 1.130 56 20 87 54 293
2024/20257.999 202 708 284 565 527 189 78 349 901 640 1.292 2.264
2025/202624.969 1.257 4.721 7.603 2.729 2.638 800 2.189 781 788 909 440 114
Totale 65.148